. 2022 Mar 16;8(1):e002160. doi: 10.1136/rmdopen-2021-002160

Table 2.

Relapse-free survival and overall survival of 727 granulomatosis with polyangiitis patients according to ANCA specificity

	Overall n=727	P value (PR3-ANCA⁺ vs MPO-ANCA⁺ vs ANCA^–)	No ANCA n=62	P value (ANCA^– vs PR3-ANCA⁺ and MPO-ANCA⁺)	MPO-ANCA⁺ n=119	P value (MPO-ANCA⁺ vs PR3-ANCA⁺ and ANCA^–)	PR3-ANCA⁺ n=546	P value (PR3-ANCA⁺ vs MPO-ANCA⁺ and ANCA^–)
Relapse-free survival
5-year (95% CI)	38.6% (34.3 to 43.4)	0.12	56.2% (43.8 to 72.1)	0.18	47.2% (36.0 to 61.7)	0.17	35.4% (30.7 to 40.9)	0.04
10-year (95% CI)	19.4% (14.7 to 25.5)	0.12	37.0% (22.7 to 60.2)	0.18	32.7% (20.5 to 52.0)	0.17	14.8% (10.0 to 21.9)	0.04
Overall survival
5-year (95% CI)	92.6% (90.3 to 95.0)	0.0058	93.0% (86.6 to 89.9)	0.92	83.9% (75.2 to 93.5)	0.001	94.2% (91.8 to 96.7)	<0.01
10-year (95% CI)	86.8% (82.9 to 90.9)	0.0058	85.7% (75.0 to 98.0)	0.92	81.5% (72.1 to 92.1)	0.001	88.1% (83.5 to 92.9)	<0.01

ANCA, antineutrophil cytoplasm antibody; MPO, myeloperoxidase; PR3, proteinase-3.